- Home
- NXE vs CRSP Comparison
NXE vs CRSP Comparison
Compare NXE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXE
- CRSP
- Stock Information
- Founded
- NXE N/A
- CRSP 2013
- Country
- NXE Canada
- CRSP Switzerland
- Employees
- NXE N/A
- CRSP N/A
- Industry
- NXE
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXE
- CRSP Health Care
- Exchange
- NXE Nasdaq
- CRSP Nasdaq
- Market Cap
- NXE 4.1B
- CRSP 3.4B
- IPO Year
- NXE N/A
- CRSP 2016
- Fundamental
- Price
- NXE $4.41
- CRSP $33.90
- Analyst Decision
- NXE
- CRSP Buy
- Analyst Count
- NXE 0
- CRSP 19
- Target Price
- NXE N/A
- CRSP $74.35
- AVG Volume (30 Days)
- NXE 10.9M
- CRSP 1.6M
- Earning Date
- NXE 03-04-2025
- CRSP 05-07-2025
- Dividend Yield
- NXE N/A
- CRSP N/A
- EPS Growth
- NXE N/A
- CRSP N/A
- EPS
- NXE N/A
- CRSP N/A
- Revenue
- NXE N/A
- CRSP $37,314,000.00
- Revenue This Year
- NXE N/A
- CRSP $49.76
- Revenue Next Year
- NXE N/A
- CRSP $257.28
- P/E Ratio
- NXE N/A
- CRSP N/A
- Revenue Growth
- NXE N/A
- CRSP N/A
- 52 Week Low
- NXE $4.44
- CRSP $36.52
- 52 Week High
- NXE $8.96
- CRSP $68.39
- Technical
- Relative Strength Index (RSI)
- NXE 34.24
- CRSP 27.61
- Support Level
- NXE $4.44
- CRSP $40.41
- Resistance Level
- NXE $5.28
- CRSP $42.72
- Average True Range (ATR)
- NXE 0.22
- CRSP 1.74
- MACD
- NXE 0.05
- CRSP -0.83
- Stochastic Oscillator
- NXE 3.87
- CRSP 1.14
About NXE Nexgen Energy Ltd.
NexGen Energy Ltd is a mineral exploration company. It is engaged in the acquisition, exploration, evaluation and development of uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin. The Rook I property hosts the world-class Arrow Zone, the Bow discovery. as well as the discovered Harpoon area located northeast of the Arrow deposit.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.